IMRX ▲ +2.1% - Immuneering Corporation
$IMRX - Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
28-SEP-2026 07:30 AM ET
Share this post
More filings for $IMRX
IMRX ▲ +1.5% - Immuneering CorporationSep 10, 2026IMRX ▼ -0.4% - Immuneering CorporationSep 3, 2026$IMRX SEC Filing Update (28-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 28, 2026
View full $IMRX filing history →💬 Comments
Loading comments…
Leave a comment